Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B2be12934510e6c9486e0f7421658c7db> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B2be12934510e6c9486e0f7421658c7db NCIT_P378 "NCI" @default.
- B2be12934510e6c9486e0f7421658c7db type Axiom @default.
- B2be12934510e6c9486e0f7421658c7db annotatedProperty IAO_0000115 @default.
- B2be12934510e6c9486e0f7421658c7db annotatedSource NCIT_C97938 @default.
- B2be12934510e6c9486e0f7421658c7db annotatedTarget "The s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression." @default.